AMYLOIDOSIS RESEARCH CONSORTIUM INC
Income Statement
Fiscal Year Start:
Jan 1
Revenues in 2024
$3,366,811
Contributions
94%
Investments
4%
Program Services
2%
Government Grants
0%
Fundraising Events
0%
Membership Dues
0%
Other
0%
Expenses in 2024
$3,016,006
Salaries & Benefits
67%
Fees to Service Providers
18%
Other
13%
Offices, Occupancy & IT
1%
Advertising & Promotion
<1%
Depreciation
<1%
Grants
0%
Benefits to Members
0%
Interest
0%
Revenues
2023
2024
Change
Contributions
$2,702,741
$3,177,624
+18%
Government Grants
$0
$0
-
Fundraising Events
$0
$0
-
Program Services
$1,525
$70,080
+4495%
Membership Dues
$0
$0
-
Investments
$54,751
$119,107
+118%
Other
$129,008
$0
-100%
Total Revenues
$2,888,025
$3,366,811
+17%
Expenses
2023
2024
Change
Grants
$0
$0
-
Benefits to Members
$0
$0
-
Salaries & Benefits
$1,497,962
$2,021,784
+35%
Fees to Service Providers
$515,982
$549,788
+7%
Advertising & Promotion
$32,788
$9,520
-71%
Offices, Occupancy & IT
$62,289
$38,231
-39%
Interest
$0
$0
-
Depreciation
$14,324
$5,757
-60%
Other
$291,714
$390,926
+34%
Total Expenses
$2,415,059
$3,016,006
+25%
Net income
2023
2024
Change
Net income
+$472,966
+$350,805
-26%
Functional Expenses
Summary
2023
2024
Change
Program
$1,548,608
$2,353,843
+52%
Admin
$341,679
$286,630
-16%
Fundraising
$524,772
$375,533
-28%
Total Expenses
$2,415,059
$3,016,006
+25%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)